Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024. Among these presentations will be late-breaking clinical data on roflumilast cream 0.05% in patients 2 to 5 years of age with mild to moderate atopic dermatitis from the pivotal INTEGUMENT-PED Phase 3 randomized controlled trial.
"Our significant presence at this year's AAD is a testament to our commitment to bringing meaningful innovation in immuno-dermatology, and building on the body of evidence supporting our topical roflumilast development program. In particular, we are excited to be participating in the late breaking data presentations with new results from INTEGUMENT-PED, as part of our atopic dermatitis clinical program," said Patrick Burnett, MD, PhD, FAAD, chief medical officer, Arcutis. "We appreciate the opportunity to participate in the AAD and other medical meetings to engage with our peers and progress the medical dermatology field."
Presentation details follow:
The following posters will be electronically available for the entirety of the conference and online beginning Friday, March 8, 2024:
Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis
Simpson, E et al.
ePoster 53863
Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM)
Bhatia, N et al.
ePoster 53894
Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR Trial
Gooderham, M et al.
ePoster 53817
Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2)
Lebwohl, M et al.
ePoster 53025
Posted In: ARQT